Opus Genetics, Inc. (IRD)
Healthcare · NCM
Price as at 1 Oct 2026, 16:37 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Opus Genetics, Inc. trades at $4.78. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 5 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
IRD dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
IRD earnings and analyst estimates
Recommendation mix, 19 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
IRD passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$9.46M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$8.00M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$2.74M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.04M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$77.8K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
IRD peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Which funds own IRD?
5 of the institutions we track reported a position in IRD in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its IRD data?
Fundamentals for IRD come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 16:37 UTC and is delayed. Our data quality score for this company is 75/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for IRD, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.